HMTXFHemostemix Inc

About Hemostemix Inc (HMTXF)

Hemostemix Inc (HMTXF) is a Biotechnology company headquartered in Calgary, AB, Canada whose shares trade over-the-counter on the OTCQB tier.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has patented the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced from the patient's blood. The Company is selling exempt compassionate treatments to individuals afflicted with critical limb ischemia, for example, and conducting clinical trials to commercialize its lead product, ACP-01, for the treatment of cardiovascular disease including chronic limb threatening ischemia (CLTI), peripheral arterial disease, Angina, hardening of the arteries (Ischemic Cardiomyopathy) thickening of the heart wall (Dilated Cardiomyopathy) and Congestive Heart Failure.

Products and services

Hemostemix’s platform technology uses a patient’s own cells to treat that patient’s disease. The cornerstone of this autologous technology is a novel cell population within each patient's blood called the synergetic cell population (SCP). The synergetic cell population is collected by a simple blood draw, then differentiated into ACP-01, NCP-01, or CCP-01. ACP-01 can be administered to a patient within 7 days of the initial cell collection (https://hemostemix.com/technology-overview/). ACP-01 has been used to treat 500 patients.

HMTXF key facts

Ticker symbol

HMTXF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Calgary, AB, Canada

Country of incorporation

CA

Year of incorporation

2014

Employees

5

Estimated market cap

$9.61M (as of Apr 16, 2025)

Shares outstanding

145,312,710

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Sep 30, 2024)

Hemostemix Inc leadership

• Thomas Smeenk — President, CEO
• Christina Wu — CFO

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with H